GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cryo-Cell International Inc (AMEX:CCEL) » Definitions » Gross Margin %

Cryo-Cell International (Cryo-Cell International) Gross Margin %

: 72.49% (As of Feb. 2024)
View and export this data going back to . Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Cryo-Cell International's Gross Profit for the three months ended in Feb. 2024 was $5.69 Mil. Cryo-Cell International's Revenue for the three months ended in Feb. 2024 was $7.85 Mil. Therefore, Cryo-Cell International's Gross Margin % for the quarter that ended in Feb. 2024 was 72.49%.


The historical rank and industry rank for Cryo-Cell International's Gross Margin % or its related term are showing as below:

CCEL' s Gross Margin % Range Over the Past 10 Years
Min: 68.45   Med: 71.52   Max: 75.03
Current: 72.79


During the past 13 years, the highest Gross Margin % of Cryo-Cell International was 75.03%. The lowest was 68.45%. And the median was 71.52%.

CCEL's Gross Margin % is ranked better than
81.02% of 606 companies
in the Healthcare Providers & Services industry
Industry Median: 41.465 vs CCEL: 72.79

Cryo-Cell International had a gross margin of 72.49% for the quarter that ended in Feb. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Cryo-Cell International was 0.80% per year.


Cryo-Cell International Gross Margin % Historical Data

The historical data trend for Cryo-Cell International's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryo-Cell International Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Gross Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.45 68.99 68.88 71.02 73.06

Cryo-Cell International Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.58 72.43 72.60 73.64 72.49

Competitive Comparison

For the Medical Care Facilities subindustry, Cryo-Cell International's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryo-Cell International Gross Margin % Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's Gross Margin % falls into.



Cryo-Cell International Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Cryo-Cell International's Gross Margin for the fiscal year that ended in Nov. 2023 is calculated as

Gross Margin % (A: Nov. 2023 )=Gross Profit (A: Nov. 2023 ) / Revenue (A: Nov. 2023 )
=22.9 / 31.344
=(Revenue - Cost of Goods Sold) / Revenue
=(31.344 - 8.443) / 31.344
=73.06 %

Cryo-Cell International's Gross Margin for the quarter that ended in Feb. 2024 is calculated as


Gross Margin % (Q: Feb. 2024 )=Gross Profit (Q: Feb. 2024 ) / Revenue (Q: Feb. 2024 )
=5.7 / 7.852
=(Revenue - Cost of Goods Sold) / Revenue
=(7.852 - 2.16) / 7.852
=72.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Cryo-Cell International  (AMEX:CCEL) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Cryo-Cell International had a gross margin of 72.49% for the quarter that ended in Feb. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Cryo-Cell International Gross Margin % Related Terms

Thank you for viewing the detailed overview of Cryo-Cell International's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryo-Cell International (Cryo-Cell International) Business Description

Traded in Other Exchanges
Address
700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of Prepacyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. All the business activity of the group functions through the United States and it derives revenue from processing and testing fees and storage fees charged each year for storage and through sales of the Prepacyte CB units.
Executives
David Portnoy director, officer: Co-Chief Executive Officer C/O FOCUS FINANCIAL GROUP, 61 HARBOUR WAY, BAL HARBOUR FL 33154
George Gaines director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Jonathan H. Wheeler director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Brian L. Sheehy director 415 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Mark L. Portnoy director, officer: Co-Chief Executive Officer 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Harold D. Berger director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Arthur Ellis director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Mary J Nyberg 10 percent owner 455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Cdmj Nyberg Family Trust 10 percent owner 455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Jill M Taymans officer: VP, Finance, CFO
Oleg Mikulinsky officer: Chief Information Officer 700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Anthony Atala director 700 BROOKER CREEK BOULEVARD, OLDSMAR FL 34677
Scott G Christian director
Sung Won Sohn director 700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Michael W. Cho director C/O IOWA STATE UNIVERSITY, 1600 S. 16TH STREET, AMES IA 50011-1250